Evp, Corporate Communications
CurrentSyncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform therapy optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially improved survival. The company is currently developing SYNC-T, a novel and personalized in situ therapy that combines partial tumor oncolysis and a multi-target biologic drug. The SYNC-T combination approach is designed to target multiple mechanisms of cancer, promoting in situ immune activation while battling immunosuppression. The goal is to activate T cells, enabling the immune system to recognize and attack cancer throughout the body. Our initial candidate, SYNC-T SV-102 for mCRPC, will begin enrolling patients in Q4-2024